1. Home
  2. MDXH vs SGMO Comparison

MDXH vs SGMO Comparison

Compare MDXH & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • SGMO
  • Stock Information
  • Founded
  • MDXH 2003
  • SGMO 1995
  • Country
  • MDXH Belgium
  • SGMO United States
  • Employees
  • MDXH N/A
  • SGMO N/A
  • Industry
  • MDXH
  • SGMO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MDXH
  • SGMO Health Care
  • Exchange
  • MDXH Nasdaq
  • SGMO Nasdaq
  • Market Cap
  • MDXH 141.1M
  • SGMO 122.8M
  • IPO Year
  • MDXH 2021
  • SGMO 2000
  • Fundamental
  • Price
  • MDXH $3.55
  • SGMO $0.52
  • Analyst Decision
  • MDXH Buy
  • SGMO Buy
  • Analyst Count
  • MDXH 1
  • SGMO 6
  • Target Price
  • MDXH $6.00
  • SGMO $4.50
  • AVG Volume (30 Days)
  • MDXH 172.3K
  • SGMO 5.9M
  • Earning Date
  • MDXH 08-05-2025
  • SGMO 08-07-2025
  • Dividend Yield
  • MDXH N/A
  • SGMO N/A
  • EPS Growth
  • MDXH N/A
  • SGMO N/A
  • EPS
  • MDXH N/A
  • SGMO N/A
  • Revenue
  • MDXH $98,953,000.00
  • SGMO $81,706,000.00
  • Revenue This Year
  • MDXH $24.77
  • SGMO $21.24
  • Revenue Next Year
  • MDXH $22.21
  • SGMO N/A
  • P/E Ratio
  • MDXH N/A
  • SGMO N/A
  • Revenue Growth
  • MDXH 22.56
  • SGMO 565.52
  • 52 Week Low
  • MDXH $1.35
  • SGMO $0.41
  • 52 Week High
  • MDXH $3.81
  • SGMO $3.18
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 73.83
  • SGMO 46.39
  • Support Level
  • MDXH $2.86
  • SGMO $0.53
  • Resistance Level
  • MDXH $3.81
  • SGMO $0.57
  • Average True Range (ATR)
  • MDXH 0.22
  • SGMO 0.04
  • MACD
  • MDXH 0.05
  • SGMO -0.00
  • Stochastic Oscillator
  • MDXH 78.15
  • SGMO 47.06

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Share on Social Networks: